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The immunolimulus (IML) assay system uses solid-phase endotoxin antibodies to capture
lipopolysaccharide (LPS), which is then quantified by a modification of the chromogenic limulus
amebocyte lysate (CLAL) method. Monoclonal antibodies (MAbs) reactive with selected 0 anti-
gen serotypes of Escherichia coli (018) and Salmonella typhimurium (0-9,12), when used in the
IML, were shown to be highly specific in detecting their respective endotoxins in purified form
and in plasma samples from experimentally infected animals. A murine MAb that was broadly
cross-reactive with E. coli, Salmonella, and Shigella endotoxins also proved to be highly effective
in the IML assay for capturing LPS molecules from both E. coli and S. typhimurium strains.
These results indicate that IML assays can detect smooth-type enterobacterial endotoxins in
plasma and suggest that such assays have potential for use in the rapid diagnosis of sepsis and
endotoxemia caused by different enterobacterial species.
As many as 600,000 episodes of sepsis occur annually in
the United States and about half of these cases are associated
with positive blood cultures [I]. About half of all cases of
sepsis are thought to be caused by gram-negative organisms
[2] and the overall case-fatality rate associated with these
infections is '"'-' 35% [3]. The incidence of severe infections
caused by gram-negative bacteria has clearly increased dur-
ing the past decade, most likely as the result of both the
better survival of severely compromised patients and the
greater use of invasive techniques in modern medicine. Ac-
cordingly, septic shock is one of the leading causes ofmortal-
ity in hospitalized patients in the United States.
Despite advances in rapid diagnostic methods used in mi-
crobiology, the diagnosis of bacteremia and sepsis caused by
gram-negative bacteria is still based on conventional and
time-consuming blood culture methods. The need to de-
velop a more rapid method for detection of gram-negative
septicemia and endotoxemia is underscored by the imminent
introduction of new and expensive antiinfective therapies,
including endotoxin-binding proteins [4, 5] and cytokine-
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directed antibodies or inhibi tors [6]. Only certain subgrou ps
of patients with sepsis or septic shock syndrome will realize
benefits from these new therapies, and thus screening and
identification of these particular persons is essential for both
medical and economic reasons [7].
New diagnostic methods for detecting bacterial endotoxin
have been investigated in our laboratory [8, 9], culminating
in the development ofa rapid method for the detection of the
lipooligosaccharide (LOS) of Haemophilus influenzae type b
(Hib). This immunolimulus (IML) assay used Hib LOS-spe-
cific monoclonal antibodies (MAbs) in a solid-phase system
to capture Hib LOS present in plasma samples from experi-
mentally infected animals [10]. This capture step provided
the necessary specificity for this method, while the requisite
sensitivity was obtained by the use of the chromogenic limu-
Ius amebocyte lysate (CLAL) assay to detect the antibody-
bound Hib LOS. We have tested the IML format for its suit-
ability for detecting enterobacterial endotoxins, using both
serotype-specific and broadly cross-reactive LPS antibodies
as capture agents.
Materials and Methods
Bacterial strains and culture conditions. Escherichia coli
o 18:K I IH3080 was isolated from a patient with neonatal men-
ingitis and has been characterized extensively [II]. Similarly, E.
coli 0 l32:K I C28 was isolated from a case of neonatal meningi-
tis in Dallas. The E. coli strains were grown in brain-heart infu-
sion broth (Difco, Detroit) at 37°C and harvested during the
midlogarithmic phase of growth. Salmonella typhimurium
SH4336 (serotype 0-4,12) and SH4338 (serotype 0-9,12) [12]
were obtained from the collection at the National Public Health
Institute, Helsinki.
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Endotoxins. Purified E. coli 0 111,0127, and 15 lipopolysac-
charides (LPS) were purchased from List Biological Laboratories
(Campbell, CA) as were Pseudomonas aeruginosa Fisher type 1
LPS and Serratia marcescens LPS. Purified LPS from E. coli
IH3080 (serotype 018) and S. typhimurium SH2183 (serotype
0-4,12) were provided by I. Helander (National Public Health
Institute). Salmonella paratyphi A IS2 (serotype 0-2,12) and
Salmonella thompson (serotype 0-6,7) were obtained from L.
LeMinor (lnstitut Pasteur, Paris) and Salmonella typhi T2 (sero-
type 0-9,12) was from B. A. D. Stocker (Stanford University
School of Medicine, Stanford, CA). These three Salmonella
strains were grown to late logarithmic phase at 37°C, and LPS
was extracted by the hot phenol-water method [13], followed
by further purification involving treatment with RNase and pro-
teinase and ultracentrifugation. LOS was purified from Hib
strain DL42 as described [14].
MAbs. One murine MAb (MATy-l 0) specific for the 0-9
epi tope of the Salmonella 0-9,12 LPS molecule was used in this
study for specific detection of the 0-9,12 endotoxin [15]. This
MAb was partly purified from ascites fluids by precipitation with
ammonium sulfate. The human MAb SE 111, reactive with E.
coli 0 18 LPS, was used in purified form and will be described in
detail elsewhere (unpublished data). The murine MAb WNI
222-5 is broadly cross-reactive with the LPS molecules ofE. coli.
Salmonella. and Shigella species [16] (unpublished data) and
was used in purified form.
Animal models. The neonatal rat model for E. coli KI infec-
tions [17] was used with some modifications. Briefly, E. coli
strains 0 18:K I and 0 132:K 1 were grown to the late logarithmic
phase in brain-heart infusion broth and harvested by centrifuga-
tion, washed once with pH 7.4 pyrogen-free (pf) PBS, and resus-
pended in this same buffer. This pf-PBS and other pf solutions
were prepared by using nonpyrogenic sterile water for irrigation
(Baxter Healthcare Products, Deerfield, IL). Five-day-old
Sprague-Dawley rat pups (Simonsen Laboratories, Gilroy, CA)
were injected intraperitoneally with 50-200 cfu of bacteria.
Twenty-four hours later, the magnitude of bacteremia in each
animal was determined by drawing 5 ~L of blood from the tail
vein and spreading it onto a brain-heart infusion agar plate.
Each animal was then immediately anesthetized, and cardiac
puncture was used to draw 0.5 mL of blood into a syringe con-
taining 0.05 mL of 3.8% (wt/vol) sodium citrate. This mixture
was centrifuged for 10 min at 5000 rpm in an Eppendorfmicro-
centrifuge (15-cm-diameter rotor; Brinkmann Instruments,
Westbury, NY), and the resultant plasma was transferred to
polypropylene tubes that were then frozen at -70°C. Furty-six
infant rats were challenged with E. coli 018:Kl; 16 animals
were injected with E. coli 0 132:K 1.
A mouse salmonellosis model [18] was used to obtain plasma
samples containing Salmonella endotoxin. Female 8-week-old
(CBA X C57BL/6) Fl mice (Bomholtgard Breeding and Re-
search Centre, Ry, Denmark) received an intraperitoneal injec-
tion of 10-50 times the LDso of S. typhimurium SH4338 and
SH4336. Animals were euthenized by CO2 narcosis at 72-144 h
after infection. Immediately after death, blood was obtained by
cardiac puncture for culture and for preparation of plasma as
described above.
Dilution fluid fiJ" purified LPS. Blood samples from normal,
uninfected infant rats and adult mice were collected by cardiac
puncture; plasma prepared from this blood was stored in multi-
ple portions at -70°C and used for dilution of the purified LPS
standards. These plasmas were diluted 1: lOin pf-PBS before
their use as diluent for purified LPS standards in those CLAL
and IML assays involving the detection of endotoxin in plasma
samples. For detection ofendotoxin in buffer, purified LPS prep-
arations were diluted in pf-PBS before USf in the CLAL and IML
assays.
LAL extract and chromogenic substra'o,. Each vial of LAL
extract (Pyrotell; Associates of Cape Coo, Woods Hole, MA),
specified as suitable for use in the CLAL assay, was rehydrated
in 10 mL of pf-water and stored in multiple portions at -20°C
for <3 months before use in the CLAL assay. When used in the
IML assay, LAL extract was rehydrated in 20 mL of pf-water
before being stored at - 20°e. The chromogenic substrate N-
benzoyl-val-gly-arg p-nitroanilide hydrochloride (Sigma, St.
Louis) was diluted to a concentration of 0.7 mg/mL in pf-water
and stored at 4°C until used.
Microtiter plates. Sterile, polystyrene 96-well ELISA plates
with flat-bottom wells (Corning Laboratory Sciences, Houston)
were used throughout this study. These plates were shown to be
pfby testing with the CLAL assay.
CLAL assay. A two-step assay system was used for detection
of endotoxin by CLAL assay in microtiter plates [8, 19]. Com-
mercially available, purified E. coli 01 11 LPS (List Biological
Laboratories) was used as the standard in all experiments. Imme-
diately before use in the CLAL assay, E. coli 0 III LPS was
diluted to concentrations of 0-800 pg of LPS/mL of dilution
fluid, heated at 75°C for 12 min [19], cooled to room tempera-
ture, and loaded in duplicate 50-,uL portions into microtiter
plates. Plasma samples from infected animals were diluted 1: 10
in pf-PBS, heated as described above, and loaded in 50-,uL por-
tions in duplicate wells. Serial 10-fold dilutions of the plasma
samples in dilution fluid were used if the initial 1: 10 dilution did
not yield an absorbance reading within the range obtained with
the LPS standards. After the addition of 50 JLL of LAL extract,
the plates were incubated for 30 min at room temperature.
Then, 50 ,uL of the chromogenic substrate. diluted 1:2 with
0.054 MTRIS-HCl, pH 9.4, immediately before use, was added
to each well and the plate was incubated for 20 min at room
temperature. The absorbance at 410 nm of the contents of each
well was determined by an automated ELISA reader (MR700;
Dynatech Laboratories, Chantilly, VA). The endotoxin content
of the test wells was determined by comparing the absorbance
values uf the test samples to those of the wells containing the
LPS standards after the background absorbances were sub-
tracted. The final endotoxin concentration was calculated by
multiplying the derived LPS concentration by the respective di-
lution factor.
IML assay. Microtiter wells were coated overnight at room
temperature with a 100-JLL volume of MAbs diluted in 0.1 M
sodium carbonate buffer, pH 9.4. The optimal concentration of
MAb for use in the IML was determined separately for each
MAb; the final amount of antibody protein added per well was
......,250 ng. Three wells were used for each endotoxin-containing
sample; two were coated with the MAb and the third was left
uncoated to serve as an internal control for specificity. The mi-
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Figure 1. Detection of purified
Escherichia coli lipopolysaccharide
(LPS) using chromogenic limulus
amebocyte lysate (CLAL) and im-
munolimulus (IML) systems.
Monoclonal antibody used in IML
system was 0 18-reactive SE I I I. E.
coli LPS used were 018, 0 I I I, and
0127. Results are means from du-
plicate wells.
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crotiter wells were washed three times with pf-PBS containing
0.05% (vol/vol) Tween-20 (pf-PBS-T) and then blocked with
pf-PBS-T containing 1% (vol/vol) fetal bovine serum (Sterile
Systems, Logan, UT). The plates were again washed with pf-
PBS-T three times.
Plasma samples from infected animals were diluted 1: lOin
pf-PBS, and the homologous LPS standard was prepared in
0-10,000 pg/mL concentrations as described above for the
CLAL assay. After heating these endotoxin-containing prepara-
tions at 75°C for 12 min, 50-1LL portions ofeach test sample and
the LPS standards were added to the microtiter wells and incu-
bated for 1 h at 37°C. The wells were then washed six times with
pf-PBS-T, and 50 1LL of LAL extract was added to each well.
After a 20-min incubation at room temperature, 50 1LL of the
chromogenic substrate was added and the absorbance in each
well was measured by an ELISA reader after 30 and 60 min. The
absorbance of the uncoated well was subtracted from the mean
of the MAb-coated wells. In instances in which the absorbances
in the uncoated wells exceeded the normal background limit
(i.e., A410 = 0.05), the samples were diluted (before use in the
IML assay) until the background absorbance was <0.05 at A41O •
The amount of LPS in the test samples was determined by
comparison with standards on each plate. The LPS standards
used in these assays varied with the MAb: Purified E. coli 018
LPS was used with the SE 1I I MAb, purified E. coli J 5 LPS was
used with cross-reactive MAb WN 1 222-5, and purified S. typhi
0-9,12 LPS was used with MATy-lO MAb.
Statistical analysis. Pearson's correlation coefficient was
used to assess the strength of the relationship between results
from the CLAL and IML assays and the magnitude ofthe bacter-
emia in the infected animals.
Results
Use ofpurified LPS to determine the sensitivity and specific-
ity of the CLAL and IML assays. The sensitivity of the
CLAL method in detecting E. coli LPS was determined using
purified preparations of E. coli 018, 01 11, and 0127 LPS.
The limit of sensitivity of the CLAL, defined as the concen-
tration of LPS yielding an absorbance (A 410) twofold higher
than the mean of the background, was 50 pg/mL with 018
LPS, 150 pg/mL with 0 III LPS, and 170 pg/mL with 0127
LPS (figure 1). All three of these purified E. coli LPS prepara-
tions were also used to determine both the sensitivity and
specificity of the IML method using the E. coli 018 LPS-
reactive MAb SE 111. Microtiter wells coated with this MAb
readily bound the homologous 018 LPS, with a detection
limit of ,....., 120 pg/mL, whereas neither the 01 11 nor the
0127 LPS molecules were reactive in this IML assay (fig-
ure 1).
Similar testing of the CLAL and IML assays was done
using purified LPS from different Salmonella strains. With
the CLAL, the limits of sensitivity for detection of four Sal-
monella LPS preparations (0-9,12, 0-4,12, 0-2,12, and
0-6,7) ranged from 20 to 50 pg/mL (figure 2). Using the
MAb MATy-l 0, which is specific for the 0-9 epitope in
0-9,12 LPS, the IML method could detect as little as 200 pg
of the homologous LPS from S. typhi but did not detect any
of the three other heterologous Salmonella LPS preparations
(figure 2).
Characterization of the broadly cross-reactive MAb WN1
222-5. This MAb has been previously described as being
reactive with the core oligosaccharide region of LPS mole-
cules from E. coli, Salmonella, and Shigella species [16] (un-
published data). Testing of this MAb in the IML system with
the various E. coli and Salmonella smooth LPS preparations
as described indicated that this MAb bound all of the differ-
ent smooth LPS molecules, with an average limit of sensitiv-
ity of ,....., 500 pg/mL. In contrast, this MAb did not detect
purified LPS (3000 pg/mL) from P. aeruginosa Fisher type 1
or S. marcescens in the IML assay. Similarly, purified LOS
(3000 pg/mL) from Hib was unreactive in the IML with
MAb WN 1 222-5 (data not shown).
Detection ofendotoxin in plasnza sanzples from experimen-
tally infected animals. The relative abilities of the IML and
CLAL assays to detect LPS in plasma were compared by
using animal models for invasive E. coli and S. typhimurium
disease. Both of the 0 antigen-specific MAbs and the
broadly cross-reactive MAb WN 1 222-5 were used for endo-
toxin capture in the IML assays. Infant rats were infected
with either E. coli 018:Kl or 0 l32:Kl, and blood was
drawn for plasma preparation 24 h after infection. Of 46
animals challenged with E. coli 0 l8:K 1,41 developed detect-
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Figure 2. Detection of purified Salmonella lipopolysaccharide (LPS) using chromogenic limulus amebocyte lysate (CLAL) and immuno-
limulus (IML) systems. Monoclonal antibody used in IML system was 0-9-reactive MATy-10, which binds 0-9,12 LPS. Serotypes of
Salmonella LPS used were 0-9,12, 0-2,12, 0-4,12, and 0-6,7. Results are means from duplicate wells.
able bacteremia (limit of detection, 200 cfu/mL). Similarly,
14 of 16 rats infected with E. coli 0 132:K 1 became bactere-
mic. Using the CLAL method. plasma from 21 (51 %) of the
41 animals with detectable E. coli 0 18:K I bacteremia
yielded a positive reaction (table 1). Similarly, of the 14 ani-
mals with E. coli 0 132:K I bacteremia. 13 (93%) had endo-
toxin detectable with the CLAL method. making a total of
34 bacteremic animals reactive in the CLAL test (table I).
The coefficient ofcorrelation between the magnitude ofbac-
teremia and detection of LPS in the CLAL assay was 0.585
for all animals in both groups; the limit of detectability of
LPS in rat plasma was 200 pg/mL (figure 3).
Table 1. Detection of endotoxin in plasma from experimentally
infected animals by means of chromogenic limulus amebocyte ly-
sate (CLAL) and immunolimulus (IML) methods.
IML(O IML
antigen- (cross-
specific)- reactive)-
CLAL- positive positive
positive plasmas/ plasmas/
plasmas/ CLAL- CLAL-
bacteremic positive positive
Challenge strain animals plasmas plasmas*
Escherichia coli
018:KI 21/41 (51) 20/21 (93)t 18/21 (86)
0132:KI 13/14(93) 0/13t 10/13(77)
Total 34/55 (62) 28/34 (82)
Sa/mollella '.l'phimllrillm
0-9,12 12/17 (71) 9/12 (75)t 10/12(83)
0-4.12 8/17 (47) 0/8 (8)t 6/8 (75)
Total 20/34 (59) 16/20 (80)
NOTE. Data are no.fno. (%).
* Using monoclonal antibody (MAb) WN I 222-5.
t Using MAb SE II I reactive with E. coli 018 lipopolysaccharide (LPS).
t Using MAb MATy-I°reactive with S. typhil1lurillll1 0-9,12 LPS.
Use of the E. coli 018 LPS-reactive MAb SE III in the
IML assay allowed detection of endotoxin in 21 (51 %) of 41
animals with E. coli 0 18:K 1 bacteremia (figure 3). Of these
21 animals. 20 had yielded positive reactions in the CLAL
(table 1). There was also 1 animal whose plasma yielded a
negative result in the CLAL but was positive in this IML
system. In contrast. none of the plasma samples from the 14
animals with E. coli 0 132:K I bacteremia had a positive reac-
tion in this IML assay (table I, figure 3). The limit of detec-
tion of E. coli 018 LPS in rat plasma with this MAb was 400
pg/mL (figure 3).
When the broadly cross-reactive MAb WN 1 222-5 was
used as the capture agent in the IML system, LPS was de-
tected in 21 (51 %) of 41 animals with E. coli 0 18:KI bacter-
emia and in 10 (71 %) of 14 that were bacteremic with the
other E. coli strain (figure 3). Of the 34 bacteremic animals
with positive plasma by CLAL, 28 were reactive with the
cross-reactive MAb in the IML (table I). The limit ofsensitiv-
ity in detecting LPS in plasma with this broadly cross-reac-
tive MAb in the IML (100 pg/mL) was roughly similar to
that achieved with the 0 antigen-reactive MAb (400 pg/
mL). although the coefficient of correlation was better with
the cross-reactive MAb (figure 3).
A mouse model of salmonellosis involving animals in-
fected with S. typhimurium SH4338 or SH4336 (LPS sero-
types 0-9,12 or 0-4,12. respectively) was also used in this
study. All 17 animals challenged with SH4338 and the 17
challenged with SH4336 became bacteremic. The limit of
sensitivity for detecting Salmonella LPS in mouse plasma
with the CLAL was 200 pg/mL, and this method detected
endotoxin in 20 of the 34 plasma samples (12 from animals
infected with strain SH4338 [serotype 0-9,12] and 8 from
animals infected with SH4336 [serotype 0-4, 12]; table 1,
figure 4). Use of the Salmonella LPS 0-9 antigen-specific
MAb MATy-l a in the IML allowed detection of LPS in 9 of
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Figure 3. Levels of Escherichia coli 0 18:K I and
o 132:K I bacteremia and concentrations of E. coli li-
popolysaccharide (LPS) detected by chromogenic lim-
ulus amebocyte lysate (CLAL) and immunolimulus
(IML) methods using monoclonal antibodies SE III
(0 antigen-specific) and WN I 222-5 (cross-reactive).
SE III binds 018 LPS but not to 0132 LPS, whereas
WN I 222-5 binds both. Correlation coefficient for
data in 0 antigen-specific IML was calculated using
results obtained with homologous LPS (018).
LPS (ng/mL)
17 plasma samples from animals infected with S. f)phil11l1r-
illl7l SH4338 (serotype 0-9,12; table l, figure 4). Of the 12
bacteremic animals infected with strain SH4338 with plasma
samples that yielded positive results in the CLAL assay, 9
were positive in the IML system using MAb MATy-l 0 (table
I, figure 4). None of the 17 plasma samples from animals
infected with the heterologous S. typhil11l1rillm SH4336 (ser-
otype 0-4,12) reacted in this 0 antigen-specific assay (table
I, figure 4). About half (16) of the 34 plasma samples
yielded a positive result with the broadly cross-reactive MAb
\VN I 222-5 in the IML system (table 1, figure 4). Among the
total 20 bacteremic animals that yielded a positive CLAL
reaction, 16 were positive in this IML using the cross-reac-
tive MAb (table I).
Discussion
The LAL test for endotoxin, while exquisitely sensitive
with in vitro samples, has several limitations when used to
detect endotoxin in clinically relevant samples, especially
plasma. First, the high degree of sensitivity of the LAL sys-
tem to endotoxin results in trace amounts of contaminating
endotoxin, derived from sampling procedures or equipment,
yielding false-positive results. Second, human plasma con-
tains several inhibitors and activators of the enzymatic sys-
tems involved in the LAL cascade [20, 21]. Third, the color
and turbidity of normal plasma lowers the sensitivity of the
CLAL, the most recent modification of the standard LAL
assay [22].
The IML method was developed specifically to circum-
vent these practical problems and possesses at least two sig-
nificant advantages over the standard CLAL method. The
use of antibodies as solid-phase endotoxin capture agents
provides specificity in the detection of a given endotoxin,
thereby alleviating the first problem described above. In ad-
dition, this endotoxin immobilization step permits thorough
washing from the test system of those plasma constituents
that adversely affect the CLAL system.
Previous experience with the IML had established that a
MAb to Hib LOS would allow detection of this endotoxin in
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Figure 4. Levels of Salmonella typhimurium
SH4338 (serotype 0-9,12) and SH4336 (serotype
0-4,12) bacteremia and concentrations of S. typhi-
murium lipopolysaccharide (LPS) as detected by
chromogenic Iimulus amebocyte lysate (CLAL) and
immunolimulus (IML) systems using monoclonal an-
tibodies MATy-I 0 (0 antigen-specific) and WN I
222-5 (cross-reactive). MAb MATy-I 0 binds 0-9.1 2
LPS whereas MAb WN I 222-5 binds both LPS mole-
cules. Correlation coefficient for data in 0 antigen-
specific IML was calculated using results obtained
with homologous LPS (0-9,12).
LPS (ng/mL)
plasma samples from experimentally infected animals [I OJ.
However, the MAb used in this earlier study bound to an
epitope in the oligosaccharide of Hib LOS, which itself is
similar to rough forms of enteric LPS molecules, being com-
posed ofonly lipid A covalently coupled to a relatively small
oligosaccharide [23]. One purpose of the present study was
to determine whether a MAb directed to an 0 antigen epi-
tope could efficiently capture smooth enteric LPS molecules
present in plasma. Using MAbs to E. coli and Salmonella 0
antigens, it was found that the corresponding smooth LPS
molecules could be detected in vitro at levels <200 pgjmL
(figures I, 2). Moreover, these same two MAbs readily de-
tected their respective LPS molecules in plasma samples ob-
tained from animals with E. coli or S. typhimurium infec-
tions, with the limit of sensitivity decreasing somewhat
(figures 3, 4). A murine MAb (E5), described as being di-
rected against E. coli J 5 LPS, was recently reported to have a
similar level of sensitivity (--250 pgjmL) in detecting puri-
fied enteric LPS molecules in buffer when used in a slightly
modified version of the IML [24]; no results using in vivo-
derived LPS-containing samples (e.g., plasma) were re-
ported.
The 0 antigen-directed MAbs used in the present study
also provided a high degree of specificity in endotoxin detec-
tion, even with plasma samples. This specificity occurred
even when levels of heterologous LPS in plasma were> 1000
ngjmL. The successful use of these 0 antigen-directed
MAbs in the IML system prompted us to evaluate a recently
described MAb that is cross-reactive with the endotoxin mol-
ecules ofall E. coli, Salmonella, and Shigella strains tested to
date [16] (unpublished data). This cross-reactive MAb
worked readily in the IML with all samples of purified E. coli
and Salmonella LPS tested in the present study and, when
used with plasma samples from the experimentally infected
animals, bound LPS from all 4 test strains (figures 3, 4). The
fact that this MAb did not bind endotoxins from other patho-
gens (P. aeruginosa and Hib) indicates that appropriate anti-
body specificity was still operative in the IML.
Direct comparison of the relative levels ofsensitivity ofthe
CLAL and IML assays was not a specific aim of this study.
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The crucial difference between these assays, however, is the
use ofextensive washing of the endotoxin immobilized in the
microtiter wells in the IML system. This efficient elimination
of interfering compounds and contaminating endotoxins
means that the sensitivity of the IML method has the poten-
tial to exceed that of the CLAL. In addition, the fact that
plasma samples used in the CLAL usually must be diluted at
least IO-fold decreases the sensitivity of this method [25]. In
contrast, samples for the IML do not have to be diluted be-
fore assay, and it is possible that multiple portions of a
plasma sample could be sequentially incubated in the IML
microtiter well, thereby increasing further the limit of sensi-
tivity for endotoxin detection.
Taken together, our results indicate that the specificity of
endotoxin detection in the IML is antibody-dependent. At
the very least, the IML may prove to be an appropriate test
vehicle for the identification of new endotoxin-directed
MAbs with therapeutic potential. In addition, the IML can
be used to screen for new endotoxin-specific MAbs that pro-
vide maximal sensitivity in detecting LPS; these MAbs
would allow improvement of the present IML technology.
The current availability of MAb WN I 222-5 and similar
cross-reactive MAbs, together with the fact that the IML
method can be completed in just 3 h, raise the possibility that
these MAbs might ultimately be incorporated into an IML-
based system for rapid detection of E. coli and Salmonella
bacteremia. Such a test, with a sensitivity comparable to that
of the CLAL and a specificity that far exceeds it, might be
useful for relatively quick identification of patients likely to
benefit from new therapeutic modalities.
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